CRBP: Corbus Pharmaceuticals Holdings Inc. Stocks News on November 25, 2025

CRBP

Associated Press Finance

13 days ago

Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

CRBP

GlobeNewswire

13 days ago

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

CRBP

GlobeNewswire

19 days ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals Announces Pricing of Public Offering

CRBP

GlobeNewswire

a month ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Announces Proposed Public Offering

CRBP

GlobeNewswire

a month ago

Corbus Pharmaceuticals Announces Proposed Public Offering

CRBP

MT Newswires

a month ago

Wedbush Raises Price Target on Corbus Pharmaceuticals Holdings to $38 From $31, Keeps Outperform Rating

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

CRBP

GlobeNewswire

a month ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

CRBP

GlobeNewswire

a month ago

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium

CRBP

GlobeNewswire

2 months ago

Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium

CRBP

MT Newswires

2 months ago

Top Premarket Decliners

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

CRBP

GlobeNewswire

5 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

CRBP

GlobeNewswire

5 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

CRBP

MT Newswires

5 months ago

Candel Therapeutics Names Charles Schoch Chief Financial Officer

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CRBP

GlobeNewswire

6 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CRBP

MT Newswires

6 months ago

Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating

CRBP

MT Newswires

6 months ago

Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP

GlobeNewswire

6 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

CRBP

GlobeNewswire

7 months ago

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

CRBP

MT Newswires

7 months ago

RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk

CRBP

Associated Press Finance

7 months ago

Corbus Pharmaceuticals: Q1 Earnings Snapshot

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

CRBP

GlobeNewswire

7 months ago

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

CRBP

Simply Wall St.

7 months ago

We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRBP

GlobeNewswire

8 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRBP

Zacks

8 months ago

After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

CRBP

Zacks

8 months ago

After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

CRBP

Zacks

8 months ago

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know

CRBP

Associated Press Finance

9 months ago

Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

CRBP

GlobeNewswire

9 months ago

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

CRBP

GlobeNewswire

9 months ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate

CRBP

Benzinga

9 months ago

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

CRBP

GlobeNewswire

9 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

CRBP

GlobeNewswire

9 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

CRBP

GlobeNewswire

10 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRBP

Insider Monkey

a year ago

Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

CRBP

MT Newswires

a year ago

Corbus Pharmaceuticals' CRB-701 Gets FDA Fast Track Designation for Treatment of Cervical Cancer

$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

CRBP

GlobeNewswire

a year ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

CRBP

Insider Monkey

a year ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now

Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

CRBP

Simply Wall St.

a year ago

We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

CRBP

Associated Press Finance

a year ago

Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

CRBP

Investor's Business Daily

a year ago

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

CRBP

GlobeNewswire

a year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals

CRBP

GuruFocus.com

a year ago

Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals

Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc

CRBP

GuruFocus.com

a year ago

Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc

CRBP

Insider Monkey

a year ago

Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts?

Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit

Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals

CRBP

GuruFocus.com

a year ago

Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals

CRBP

MT Newswires

a year ago

Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $42 From $74, Keeps Outperform Rating

CRBP

MT Newswires

a year ago

B. Riley Cuts Price Target on Corbus Pharmaceuticals Holdings to $40 From $85, Keeps Buy Rating

Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players

CRBP

Benzinga

a year ago

Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players

Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

CRBP

Insider Monkey

a year ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now

CRBP

Insider Monkey

a year ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer’s Top Stock Picks For the Next 12 Months

CRBP

Zacks

a year ago

Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

CRBP

Simply Wall St.

a year ago

With 59% ownership, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) boasts of strong institutional backing

CRBP

Zacks

a year ago

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why

CRBP

Zacks

a year ago

Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade

CRBP

MT Newswires

a year ago

Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $88 From $80, Maintains Outperform Rating

CRBP

Associated Press Finance

a year ago

Corbus Pharmaceuticals: Q2 Earnings Snapshot

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

CRBP

MT Newswires

a year ago

Wedbush Initiates Corbus Pharmaceuticals at Outperform With $85 Price Target

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

CRBP

GlobeNewswire

a year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

CRBP

GlobeNewswire

a year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

CRBP

GlobeNewswire

2 years ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

CRBP

Associated Press Finance

2 years ago

Corbus Pharmaceuticals: Q1 Earnings Snapshot

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

CRBP

GlobeNewswire

2 years ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

CRBP

Associated Press Finance

2 years ago

Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

CRBP

Simply Wall St.

2 years ago

Retail investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) are its biggest bettors, and their bets paid off as stock gained 214% last week

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

CRBP

GlobeNewswire

2 years ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

CRBP

News Direct

2 years ago

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

CRBP

GlobeNewswire

2 years ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Home Federal Bancorp Inc of louisiana's Dividend Analysis

CRBP

GuruFocus.com

2 years ago

Home Federal Bancorp Inc of louisiana's Dividend Analysis

GoldMining Subsidiary, U.S. GoldMining, Announces Confirmatory Results, Including Highest Drill Intercept to Date at the Whistler Gold-Copper Project, Alaska

CRBP

CNW Group

2 years ago

GoldMining Subsidiary, U.S. GoldMining, Announces Confirmatory Results, Including Highest Drill Intercept to Date at the Whistler Gold-Copper Project, Alaska

Purple Innovation Strengthens Balance Sheet, Creating Greater Financial Flexibility to Execute Growth Strategy

CRBP

PR Newswire

2 years ago

Purple Innovation Strengthens Balance Sheet, Creating Greater Financial Flexibility to Execute Growth Strategy

CRBP

GlobeNewswire

2 years ago

NUBIA BRAND INTERNATIONAL CORP. CONFIRMS PRIOR UPDATE ON REDEMPTION REVERSAL REQUESTS IN CONNECTION WITH CLOSING ITS BUSINESS COMBINATION

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

CRBP

GlobeNewswire

2 years ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)

CRBP

GlobeNewswire

2 years ago

SANUWAVE Announces Special Meeting of Stockholders to Vote on Business Combination with SEP Acquisition Corp. (Nasdaq: SEPA)

At US$16.29, Is DLH Holdings Corp. (NASDAQ:DLHC) Worth Looking At Closely?

CRBP

Simply Wall St.

2 years ago

At US$16.29, Is DLH Holdings Corp. (NASDAQ:DLHC) Worth Looking At Closely?

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

CRBP

Zacks

2 years ago

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

CRBP

GlobeNewswire

2 years ago

NUBIA BRAND INTERNATIONAL CORP. PROVIDES UPDATE ON REDEMPTION REVERSAL REQUESTS IN CONNECTION WITH CLOSING ITS BUSINESS COMBINATION

abrdn U.S. Closed End Funds Announce Distribution Payment Details

CRBP

ACCESSWIRE

2 years ago

Latest Corbus Pharmaceuticals Holdings Inc. (CRBP) News on November 25, 2025

Share on Social Networks: